CYTK — Cytokinetics Cashflow Statement
0.000.00%
Last trade - 00:00- $4.82bn
- $4.40bn
- $18.47m
Annual cashflow statement for Cytokinetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -127 | -215 | -389 | -526 | -590 |
| Depreciation | |||||
| Non-Cash Items | 46.5 | 62.1 | 108 | 96.9 | 148 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 87.9 | 8.46 | -24.7 | 3.09 | 35.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 8.94 | -143 | -300 | -414 | -396 |
| Capital Expenditures | -11.1 | -48.9 | -11.3 | -1.42 | -3.91 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -185 | -98.9 | -251 | 241 | -549 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -197 | -148 | -262 | 239 | -553 |
| Financing Cash Flow Items | 2.15 | 0 | 14.4 | -10.5 | -19.6 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 234 | 320 | 516 | 221 | 931 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 46.6 | 29.7 | -45.5 | 46.2 | -18.2 |